Workflow
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
GSKGSK(GSK) Benzinga·2024-06-18 17:44

Loading... Cantor projects around $1.1 billion of 5-year projected royalty revenues from GSK and initiates Innoviva with an Overweight rating. The company plans to expand Innoviva Specialty Therapeutics' product portfolio through organic and inorganic growth opportunities. Zoliflodacin could achieve over $500 million of annual peak sales in the U.S. Price Action: INVA shares are up 1.61% at $16.42 at last check Tuesday. Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's un ...